KLRS Kalaris Therapeutics, Inc.
$3.38▲ +2.42%
Healthcare
Other
After hours
$3.48▲ +2.96%
Sep 11, 7:30 PM ET
Volume 87.1K
Avg Volume (10D) 56.4K
Key Metrics & Fundamentals
Market Cap
$80.46M
P/E Ratio
–
Div Yield
–%
52W Range
3.03 - 11.88
% vs 50 MA
-16.65%
% vs 200 MA
-46.94%
RSI-14
31.9
MACD Histogram
-0.0700
Beta (1Y vs SPY)
0.98
Free Cash Flow
-$11.05M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$11.51M
COGS
–
Operating Exp
$12.39M
Operating Income
-$12.39M
EBIT
-$12.39M
Pretax Income
-$11.52M
Net Income
-$11.52M
EPS (Diluted)
-0.48
Price & Volume History
Loading chart…
Recent News
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Aug 31, 2026 12:00 PM
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 11, 2026 12:00 PM
Kalaris Therapeutics Names Liisa Bayko CFO
MT Newswires · Jul 20, 2026 1:29 PM
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
GlobeNewswire · Jul 20, 2026 12:00 PM
Top Midday Gainers
MT Newswires · Jul 17, 2026 5:51 PM
Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD
MT Newswires · Jul 17, 2026 11:44 AM
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
GlobeNewswire · Jul 17, 2026 11:00 AM
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
Insider Monkey · Jul 14, 2026 6:07 PM
Kalaris Appoints Laurie Keating to Board of Directors
GlobeNewswire · Jul 6, 2026 8:05 PM
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
GlobeNewswire · Jun 23, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See KLRS's money flow as a full page
Social Sentiment
Avg +0.70 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.